To examine the clinical effects of mesoglycan in patients with chronic venous disease (CVD) or hemorrhoidal disease (HD) and its mechanism of action, highlighting its potential impact on patient outcomes.
Key Findings:
CVD affects 22–41% and HD 11–39% of the population in Europe.
CVD symptoms include aching, heaviness, cramps, and may lead to complications like venous ulcers.
Mesoglycan is a natural preparation of glycosaminoglycans effective in treating CVD and HD, with evidence supporting its clinical efficacy.
Interpretation:
Mesoglycan may modify underlying pathophysiological processes in CVD and HD, potentially improving patient outcomes by enhancing vascular health.
Limitations:
Lack of focused reviews on mesoglycan specifically, with variability in study quality and methodologies affecting the reliability of findings.
Conclusion:
Mesoglycan shows promise in treating CVD and HD, warranting further investigation into its clinical efficacy, mechanisms, and potential long-term benefits.
The Vascular Surgery Fellowship, which is accredited by the Accreditation Council for Graduate Medical Education (ACGME), is a program of Cedars-Sinai, an academic medical center renowned for vascular care, research and education. Cedars-Sinai is consistently ranked one of the nation's best hospitals by U.S. News & World Report.
